Motor Phenotype of LRRK2 G2019S Carriers in Early-Onset Parkinson Disease

被引:0
|
作者
Alcalay, Roy N. [1 ]
Mejia-Santana, Helen [1 ]
Tang, Ming Xin [1 ,3 ]
Rosado, Llency [1 ]
Verbitsky, Miguel [3 ]
Kisselev, Sergey [3 ]
Ross, Barbara M. [3 ]
Louis, Elan D. [1 ,3 ,4 ,6 ]
Comella, Cynthia L. [12 ]
Colcher, Amy [16 ]
Jennings, Danna [14 ]
Nance, Martha A. [17 ]
Bressman, Susan [8 ,9 ]
Scott, William K. [18 ]
Tanner, Caroline [21 ]
Mickel, Susan F. [20 ]
Andrews, Howard F. [10 ]
Waters, Cheryl H. [1 ]
Fahn, Stanley [1 ]
Cote, Lucien J. [4 ]
Frucht, Steven J. [1 ]
Ford, Blair [1 ]
Rezak, Michael [11 ,13 ]
Novak, Kevin [11 ,13 ]
Friedman, Joseph H. [22 ,23 ]
Pfeiffer, Ronald [24 ]
Marsh, Laura [25 ,26 ]
Hiner, Bradley [19 ]
Siderowf, Andrew [15 ]
Caccappolo, Elise [3 ]
Ottman, Ruth [4 ,6 ]
Clark, Lorraine N. [2 ,3 ,5 ]
Marder, Karen S. [1 ,3 ,4 ,7 ]
机构
[1] Columbia Univ, Dept Neurol, New York, NY 10032 USA
[2] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA
[3] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA
[4] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA
[5] Columbia Univ, Coll Phys & Surg, Ctr Human Genet, New York, NY 10032 USA
[6] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA
[7] Columbia Univ, Med Ctr, Dept Psychiat, New York, NY 10032 USA
[8] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[9] Albert Einstein Coll Med, Beth Israel Med Ctr, Alan & Barbara Mirken Dept Neurol, Bronx, NY 10467 USA
[10] Albert Einstein Coll Med, Data Coordinating Ctr, New York State Psychiat Inst, Bronx, NY 10467 USA
[11] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL USA
[12] Rush Univ, Dept Neurol, Movement Disorder Sect, Chicago, IL 60612 USA
[13] NorthShore Univ HealthSyst, Dept Neurol, Evanston, IL USA
[14] Inst Neurodegenerat Disorders, New Haven, CT USA
[15] Univ Penn Hlth Syst, Dept Neurol, Philadelphia, PA USA
[16] Univ Penn Hlth Syst, Parkinsons Dis & Movement Disorders Ctr, Penn Hosp, Philadelphia, PA USA
[17] Park Nicollet Clin, Struthers Parkinsons Ctr, Golden Valley, MN USA
[18] Univ Miami, Miller Sch Med, Dept Human Genet, Miami Inst Human Genom,Dr John T Macdonald Fdn, Miami, FL 33136 USA
[19] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[20] Marshfield Clin Fdn Med Res & Educ, Dept Neurol, Marshfield, WI USA
[21] Parkinsons Inst, Sunnyvale, CA USA
[22] Parkinsons Dis & Movement Disorders Ctr NeuroHlth, Warwick, England
[23] Brown Univ, Warren Alpert Sch Med, Dept Clin Neurosci, Providence, RI 02912 USA
[24] Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Neurol, Memphis, TN 38163 USA
[25] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci & Neurol & Neurol Sci, Baltimore, MD USA
[26] Johns Hopkins Univ, Morris K Udall Parkinsons Dis Res Ctr Excellence, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
TREMOR-DOMINANT PARKINSONISM; LEWY BODIES; MUTATION; DEMENTIA; GENE; SUBTYPE;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine the motor phenotype of LRRK2 G2019S mutation carriers. LRRK2 mutation carriers were previously reported to manifest the tremor dominant motor phenotype, which has been associated with slower motor progression and less cognitive impairment compared with the postural instability and gait difficulty (PIGD) phenotype. Design: Cross-sectional observational study. Setting: Thirteen movement disorders centers. Participants: Nine hundred twenty-five early-onset Parkinson disease cases defined as age at onset younger than 51 years. Main Outcome Measures: LRRK2 mutation status and Parkinson disease motor phenotype: tremor dominant or PIGD. Demographic information, family history of Parkinson disease, and the Unified Parkinson's Disease Rating Scale score were collected on all participants. DNA samples were genotyped for LRRK2 mutations (G2019S, I2020T, R1441C, and Y1699C). Logistic regression was used to examine associations of G2019S mutation status with motor phenotype adjusting for disease duration, Ashkenazi Jewish ancestry, levodopa dose, and family history of Parkinson disease. Results: Thirty-four cases (3.7%) (14 previously reported) were G2019S carriers. No other mutations were found. Carriers were more likely to be Ashkenazi Jewish (55.9% vs 11.9%; P < .001) but did not significantly differ in any other demographic or disease characteristics. Carriers had a lower tremor score (P=.03) and were more likely to have a PIGD phenotype (92.3% vs 58.9%; P=.003). The association of the G2019S mutation with PIGD phenotype remained after controlling for disease duration and Ashkenazi Jewish ancestry (odds ratio, 17.7; P<.001). Conclusion: Early-onset Parkinson disease G2019S LRRK2 carriers are more likely to manifest the PIGD phenotype, which may have implications for disease course.
引用
收藏
页码:1517 / 1522
页数:6
相关论文
共 50 条
  • [21] LRRK2 G2019S mutation in Parkinson's disease: A neuropsychological and neuropsychiatric study in a large Algerian cohort
    Belarbi, Soreya
    Hecham, Nassima
    Lesage, Suzanne
    Kediha, Mohamed I.
    Smail, Nourredine
    Benhassine, Traki
    Ysmail-Dahlouk, Farida
    Lohman, Ebba
    Benhabyles, Badia
    Hamadouche, Tank
    Assami, Salima
    Brice, Alexis
    Tazir, Meriem
    PARKINSONISM & RELATED DISORDERS, 2010, 16 (10) : 676 - 679
  • [22] Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD
    Poulopoulos, Markos
    Cortes, Etty
    Vonsattel, Jean-Paul G.
    Fahn, Stanley
    Waters, Cheryl
    Cote, Lucien J.
    Moskowitz, Carol
    Honig, Lawrence S.
    Clark, Lorraine N.
    Marder, Karen S.
    Alcalay, Roy N.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2012, 47 (01) : 139 - 143
  • [23] Lower cognitive performance in healthy G2019S LRRK2 mutation carriers
    Thaler, Avner
    Mirelman, Anat
    Gurevich, Tanya
    Simon, Ely
    Orr-Urtreger, Avi
    Marder, Karen
    Bressman, Susan
    Giladi, Nir
    NEUROLOGY, 2012, 79 (10) : 1027 - 1032
  • [24] Clinical Expression of LRRK2 G2019S Mutations in the Elderly
    San Luciano, Marta
    Lipton, Richard B.
    Wang, Cuiling
    Katz, Mindy
    Zimmerman, Molly E.
    Sanders, Amy E.
    Ozelius, Laurie J.
    Bressman, Susan B.
    Saunders-Pullman, Rachel
    MOVEMENT DISORDERS, 2010, 25 (15) : 2571 - 2576
  • [25] The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease
    Kalinderi, K.
    Fidani, L.
    Bostantjopoulou, S.
    Katsarou, Z.
    Kotsis, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (10) : 1088 - 1090
  • [26] Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease
    Bialecka, M
    Hui, S
    Klodowska-Duda, G
    Opala, G
    Tan, EK
    Drozdzik, M
    NEUROSCIENCE LETTERS, 2005, 390 (01) : 1 - 3
  • [27] Prevalence of Cancer in Parkinson's Disease Related to R1441G and G2019S Mutations in LRRK2
    Ruiz-Martinez, Javier
    de la Riva, Patricia
    Rodriguez-Oroz, Maria C.
    Mondragon Rezola, Elisabet
    Bergareche, Alberto
    Gorostidi, Ana
    Gago, Belen
    Estanga, Ainara
    Larranaga, Nerea
    Sarasqueta, Cristina
    Lopez de Munain, Adolfo
    Marti Masso, Jose F.
    MOVEMENT DISORDERS, 2014, 29 (06) : 750 - 755
  • [28] A meta-analysis of the prevalence of the mutation LRRK2 G2019S in patients with Parkinson's disease in Africa
    Wahmane, Sofiane Ait
    Achbani, Abderrahmane
    Elatiqi, Mohamed
    Belmouden, Ahmed
    Nejmeddine, Mohamed
    GENE REPORTS, 2021, 24
  • [29] Heartbeat signature for predicting motor and non-motor involvement among nonparkinsonian LRRK2 G2019S mutation carriers
    Carricarte Naranjo, Claudia
    Marras, Connie
    Visanji, Naomi P.
    Cornforth, David J.
    Sanchez-Rodriguez, Lazaro
    Schule, Birgitt
    Goldman, Samuel M.
    Estevez, Mario
    Stein, Phyllis K.
    Jelinek, Herbert F.
    Lang, Anthony E.
    Machado, Andres
    CLINICAL AUTONOMIC RESEARCH, 2025, : 407 - 419
  • [30] Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD
    Markos Poulopoulos
    Etty Cortes
    Jean-Paul G. Vonsattel
    Stanley Fahn
    Cheryl Waters
    Lucien J. Cote
    Carol Moskowitz
    Lawrence S. Honig
    Lorraine N. Clark
    Karen S. Marder
    Roy N. Alcalay
    Journal of Molecular Neuroscience, 2012, 47 : 139 - 143